FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109953138> ?p ?o ?g. }

• W3109953138 endingPage "e602" @default.
• W3109953138 startingPage "e597" @default.
• W3109953138 abstract "Abstract Background Fluoropyrimidines are used in chemotherapy combinations for multiple cancers. Deficient dihydropyrimidine dehydrogenase activity can lead to severe life-threatening toxicities. DPYD*2A polymorphism is one of the most studied variants. The study objective was to document the impact of implementing this test in routine clinical practice. Methods We retrospectively performed chart reviews of all patients who tested positive for a heterozygous or homozygous DPYD*2A mutation in samples obtained from patients throughout the province of Quebec, Canada. Results During a period of 17 months, 2,617 patients were tested: 25 patients tested positive. All were White. Twenty-four of the 25 patients were heterozygous (0.92%), and one was homozygous (0.038%). Data were available for 20 patients: 15 were tested upfront, whereas five were identified after severe toxicities. Of the five patients confirmed after toxicities, all had grade 4 cytopenias, 80% grade ≥3 mucositis, 20% grade 3 rash, and 20% grade 3 diarrhea. Eight patients identified with DPYD*2A mutation prior to treatment received fluoropyrimidine-based chemotherapy at reduced initial doses. The average fluoropyrimidine dose intensity during chemotherapy was 50%. No grade ≥3 toxicities were observed. DPYD*2A test results were available in an average of 6 days, causing no significant delays in treatment initiation. Conclusion Upfront genotyping before fluoropyrimidine-based treatment is feasible in clinical practice and can prevent severe toxicities and hospitalizations without delaying treatment initiation. The administration of chemotherapy at reduced doses appears to be safe in patients heterozygous for DPYD*2A. Implications for Practice Fluoropyrimidines are part of chemotherapy combinations for multiple cancers. Deficient dihydropyrimidine dehydrogenase activity can lead to severe life-threatening toxicities. This retrospective analysis demonstrates that upfront genotyping of DPYD before fluoropyrimidine-based treatment is feasible in clinical practice and can prevent severe toxicities and hospitalizations without delaying treatment initiation. This approach was reported previously, but insufficient data concerning its application in real practice are available. This is likely the first reported experience of systematic DPYD genotyping all over Canada and North America as well." @default.
• W3109953138 created "2020-12-07" @default.
• W3109953138 creator A5000120535 @default.
• W3109953138 creator A5008088780 @default.
• W3109953138 creator A5018835840 @default.
• W3109953138 creator A5020900490 @default.
• W3109953138 creator A5027454366 @default.
• W3109953138 creator A5030958915 @default.
• W3109953138 creator A5032279767 @default.
• W3109953138 creator A5034580946 @default.
• W3109953138 creator A5038106718 @default.
• W3109953138 creator A5040194713 @default.
• W3109953138 creator A5042898910 @default.
• W3109953138 creator A5042946684 @default.
• W3109953138 creator A5045449197 @default.
• W3109953138 creator A5064078958 @default.
• W3109953138 creator A5065090308 @default.
• W3109953138 creator A5065265203 @default.
• W3109953138 creator A5067138875 @default.
• W3109953138 creator A5071219496 @default.
• W3109953138 creator A5075835036 @default.
• W3109953138 creator A5090920989 @default.
• W3109953138 date "2020-12-23" @default.
• W3109953138 modified "2023-10-02" @default.
• W3109953138 title "Implementing <i>DPYD*2A</i> Genotyping in Clinical Practice: The Quebec, Canada, Experience" @default.
• W3109953138 cites W1774948393 @default.
• W3109953138 cites W1918208609 @default.
• W3109953138 cites W1966968583 @default.
• W3109953138 cites W1984328540 @default.
• W3109953138 cites W2014636014 @default.
• W3109953138 cites W2097101234 @default.
• W3109953138 cites W2105763971 @default.
• W3109953138 cites W2110519215 @default.
• W3109953138 cites W2119270435 @default.
• W3109953138 cites W2140626944 @default.
• W3109953138 cites W2141768150 @default.
• W3109953138 cites W2143378856 @default.
• W3109953138 cites W2148894794 @default.
• W3109953138 cites W2174633205 @default.
• W3109953138 cites W2274849119 @default.
• W3109953138 cites W2470575266 @default.
• W3109953138 cites W2606453095 @default.
• W3109953138 cites W2740881191 @default.
• W3109953138 cites W2788695304 @default.
• W3109953138 cites W2896913847 @default.
• W3109953138 cites W2903768375 @default.
• W3109953138 cites W3088902621 @default.
• W3109953138 doi "https://doi.org/10.1002/onco.13626" @default.
• W3109953138 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8018309" @default.
• W3109953138 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33274825" @default.
• W3109953138 hasPublicationYear "2020" @default.
• W3109953138 type Work @default.
• W3109953138 sameAs 3109953138 @default.
• W3109953138 citedByCount "13" @default.
• W3109953138 countsByYear W31099531382020 @default.
• W3109953138 countsByYear W31099531382021 @default.
• W3109953138 countsByYear W31099531382022 @default.
• W3109953138 countsByYear W31099531382023 @default.
• W3109953138 crossrefType "journal-article" @default.
• W3109953138 hasAuthorship W3109953138A5000120535 @default.
• W3109953138 hasAuthorship W3109953138A5008088780 @default.
• W3109953138 hasAuthorship W3109953138A5018835840 @default.
• W3109953138 hasAuthorship W3109953138A5020900490 @default.
• W3109953138 hasAuthorship W3109953138A5027454366 @default.
• W3109953138 hasAuthorship W3109953138A5030958915 @default.
• W3109953138 hasAuthorship W3109953138A5032279767 @default.
• W3109953138 hasAuthorship W3109953138A5034580946 @default.
• W3109953138 hasAuthorship W3109953138A5038106718 @default.
• W3109953138 hasAuthorship W3109953138A5040194713 @default.
• W3109953138 hasAuthorship W3109953138A5042898910 @default.
• W3109953138 hasAuthorship W3109953138A5042946684 @default.
• W3109953138 hasAuthorship W3109953138A5045449197 @default.
• W3109953138 hasAuthorship W3109953138A5064078958 @default.
• W3109953138 hasAuthorship W3109953138A5065090308 @default.
• W3109953138 hasAuthorship W3109953138A5065265203 @default.
• W3109953138 hasAuthorship W3109953138A5067138875 @default.
• W3109953138 hasAuthorship W3109953138A5071219496 @default.
• W3109953138 hasAuthorship W3109953138A5075835036 @default.
• W3109953138 hasAuthorship W3109953138A5090920989 @default.
• W3109953138 hasBestOaLocation W31099531381 @default.
• W3109953138 hasConcept C104317684 @default.
• W3109953138 hasConcept C121608353 @default.
• W3109953138 hasConcept C123321153 @default.
• W3109953138 hasConcept C126322002 @default.
• W3109953138 hasConcept C135763542 @default.
• W3109953138 hasConcept C141071460 @default.
• W3109953138 hasConcept C143998085 @default.
• W3109953138 hasConcept C2776694085 @default.
• W3109953138 hasConcept C2777909004 @default.
• W3109953138 hasConcept C2778050828 @default.
• W3109953138 hasConcept C2778496288 @default.
• W3109953138 hasConcept C2778570526 @default.
• W3109953138 hasConcept C2779655350 @default.
• W3109953138 hasConcept C2780456651 @default.
• W3109953138 hasConcept C31467283 @default.
• W3109953138 hasConcept C526805850 @default.
• W3109953138 hasConcept C54355233 @default.
• W3109953138 hasConcept C55775858 @default.

• next